

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Email: zelano@mwzb.com

AJZ:jmm

FILED: 22 JUNE 2001

09869000-062201
T02230-00069860

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 3, 5-9 and 12-13 have been amended as follows:

3. (Amended) Testosterone derivatives according to claim 1 ~~or 2~~, wherein R^{17b} is the hydroxy group, a C₁-C₅ alkoxy group or a C₁-C₃ alkanoyloxy group.

5. (Amended) Testosterone derivatives according to ~~one of~~ claims 1 ~~to 4~~, wherein R⁶ represents a hydrogen atom, the hydroxy group or a halogen atom.

6. (Amended) Testosterone derivatives according to ~~one of~~ claims 1 ~~to 5~~, wherein R¹⁵ and R¹⁶ each represent a hydrogen atom.

7. (Amended) Testosterone derivatives according to ~~one of~~ claims 1 ~~to 6~~, wherein radical ABCD means 9-hydroxynonyl, 7-(acetylsulfanyl)heptyl or 7-(4-cyanobutoxy)heptyl.

8. (Amended) Testosterone derivatives according to ~~one of~~ claims 1 ~~to 6~~, wherein the five-ring- or six-ring-heteroaromatic compounds of radical C are pyrrole, thiophene, imidazole, thiazole, oxazole, triazole, thiadiazole, indole, benzoxazole, benzothiazole, pyridine, or pyrimidine.

9. (Amended) Testosterone derivatives according to ~~one of~~ claims 1 ~~to 8~~, wherein they represent the following compounds:

7 α -(9-Chlorononyl)-17 α -methyl-3-oxoandrost-4-en-17 β -yl-acetate

7 α -(9-Chlorononyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-7 α -(9-iodononyl)-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-7 α -(9-hydroxynonyl)-17 α -methylandrost-4-en-3-one

7 α -(10-Chlorodecyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-7 α -(11-hydroxyundecyl)-17 α -methylandrost-4-en-3-one

7 α -(11-Bromoundecyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-17 α -methyl-7 α -[7-(phenylsulfanyl)heptyl]androst-4-en-3-one

17 β -Hydroxy-17 α -methyl-7 α -[9-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]nonyl]androst-4-en-3-one

17 β -Hydroxy-17 α -methyl-7 α -[9-(phenylsulfanyl)nonyl]androst-4-en-3-one

7 α -[9-[(5-Chloropentyl)sulfanyl]nonyl]-17 β -hydroxy-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-7 α -[9-[(5-hydroxypentyl)sulfanyl]nonyl]-17 α -methylandrost-4-en-3-one

7 α -(9-Azidononyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one

7 α -[7-(Acetylsulfanyl)heptyl]-17 β -hydroxy-17 α -methylandrost-4-en-3-one

17 β -Hydroxy-17 α -methyl-7 α -[7-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]heptyl]androst-4-en-3-one

N-[7-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)heptyl]pentanamide

17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -octane nitrile

5-[[7-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)heptyl]oxy]pentanenitrile

17 β -Hydroxy-17 α -methyl-7 α -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]androst-4-en-3-one

N-[9-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)nonyl]methanesulfonamide

7 α -(9-Chlorononyl)-6 β -hydroxy-17 α -methyl-3-oxoandrost-4-en-17 β -yl-acetate

12. (Amended) Use according to claim 10 ~~or 11~~, wherein the testosterone derivatives that are described in more detail in Claims 2 to 9 of general formula I are used.

13. (Amended) Pharmaceutical agents that contain at least one testosterone derivative of general formula I according to claims 1 to 9 and physiologically compatible adjuvants and/or vehicles that are commonly used in galenicals.